Detalhe da pesquisa
1.
Nucleic Acid Polymers are Effective in Targeting Hepatitis B Surface Antigen, but More Trials Are Needed.
Gastroenterology
; 158(8): 2051-2054, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32311360
2.
Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.
Ann Hepatol
; 15(3): 333-49, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27049487
3.
STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.
J Hepatol
; 62(6): 1246-55, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25559324
4.
Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis C.
J Virol
; 88(11): 6394-402, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24672032
5.
HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients.
Liver Int
; 35 Suppl 1: 82-90, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25529092
6.
Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients.
Antimicrob Agents Chemother
; 58(9): 5332-41, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24982076
7.
SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients.
Antimicrob Agents Chemother
; 58(6): 3429-36, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24709256
8.
Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.
Hepatology
; 57(6): 2143-54, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23359516
9.
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.
Hepatology
; 57(6): 2155-63, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23504636
10.
HCV direct-acting antiviral agents: the best interferon-free combinations.
Liver Int
; 34 Suppl 1: 69-78, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24373081
11.
HBsAg quantification: useful for monitoring natural history and treatment outcome.
Liver Int
; 34 Suppl 1: 97-107, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24373085
12.
Interferon free therapy with direct acting antivirals for HCV.
Liver Int
; 33 Suppl 1: 93-104, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23286852
13.
The role of HBsAg quantification for monitoring natural history and treatment outcome.
Liver Int
; 33 Suppl 1: 125-32, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23286856
14.
Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow.
Liver Int
; 32 Suppl 1: 88-102, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-22212578
15.
Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.
Hepatology
; 51(4): 1122-6, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20069649
16.
New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
Liver Int
; 31 Suppl 1: 68-77, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21205141
17.
Optimism for patients with genotype 4 HCV infection: clinical trials with direct-acting antivirals finally available.
J Hepatol
; 62(5): 996-9, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25747660
18.
Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis.
J Hepatol
; 52(5): 652-7, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20346533
19.
Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.
Hepatology
; 49(4): 1151-7, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-19115222
20.
Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin.
Liver Int
; 30(9): 1259-69, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20633102